Mark A. Burlingame

543 total citations
18 papers, 424 citations indexed

About

Mark A. Burlingame is a scholar working on Molecular Biology, Organic Chemistry and Oncology. According to data from OpenAlex, Mark A. Burlingame has authored 18 papers receiving a total of 424 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 9 papers in Organic Chemistry and 6 papers in Oncology. Recurrent topics in Mark A. Burlingame's work include Cancer Treatment and Pharmacology (6 papers), Synthetic Organic Chemistry Methods (5 papers) and Microbial Natural Products and Biosynthesis (4 papers). Mark A. Burlingame is often cited by papers focused on Cancer Treatment and Pharmacology (6 papers), Synthetic Organic Chemistry Methods (5 papers) and Microbial Natural Products and Biosynthesis (4 papers). Mark A. Burlingame collaborates with scholars based in United States, Puerto Rico and South Korea. Mark A. Burlingame's co-authors include Matthew P. Jacobson, Jack Sadowsky, Dennis W. Wolan, Christopher L. McClendon, James A. Wells, Simon J. Shaw, David C. Myles, Kurt F. Sundermann, B. Scott Freeze and Amos B. Smith and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and Journal of Bacteriology.

In The Last Decade

Mark A. Burlingame

18 papers receiving 399 citations

Peers

Countries citing papers authored by Mark A. Burlingame

Since Specialization

Citations

This map shows the geographic impact of Mark A. Burlingame's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark A. Burlingame with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark A. Burlingame more than expected).

Fields of papers citing papers by Mark A. Burlingame

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark A. Burlingame. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark A. Burlingame. The network helps show where Mark A. Burlingame may publish in the future.

Co-authorship network of co-authors of Mark A. Burlingame

This figure shows the co-authorship network connecting the top 25 collaborators of Mark A. Burlingame. A scholar is included among the top collaborators of Mark A. Burlingame based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark A. Burlingame. Mark A. Burlingame is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work	Indexed citations
1	TPT sulfonate, a single, oral dose schistosomicidal prodrug: In vivo efficacy, disposition and metabolic profiling 2018 ·International Journal for Parasitology Drugs and Drug Resistance ·Alan R. Wolfe, R. Jeffrey Neitz, Mark A. Burlingame, Brian M. Suzuki, K. C. Lim, Mark A. Scheideler, David Lee Nelson, Leslie Z. Benet, Conor R. Caffrey	7
2	Identification and Optimization of Thienopyridine Carboxamides as Inhibitors of HIV Regulatory Complexes 2017 ·Antimicrobial Agents and Chemotherapy ·Robert L. Nakamura, Mark A. Burlingame, Shumin Yang, David C. Crosby, Dale Talbot, (unknown), Alan D. Frankel, Adam R. Renslo	10
3	Capture of micrococcin biosynthetic intermediates reveals C-terminal processing as an obligatory step for in vivo maturation 2016 ·Proceedings of the National Academy of Sciences ·(unknown), (unknown), Mark A. Burlingame, Richard A. Robison, Joel S. Griffitts, Susan M. Miller	19
4	Reconstitution and Minimization of a Micrococcin Biosynthetic Pathway in Bacillus subtilis 2016 ·Journal of Bacteriology ·(unknown), (unknown), Mark A. Burlingame, Richard A. Robison, Susan M. Miller, Joel S. Griffitts	17
5	Intervention to Decrease Glyburide Use in Elderly Patients With Renal Insufficiency 2011 ·The American journal of geriatric pharmacotherapy ·Sherrie L. Aspinall, Xinhua Zhao, Chester B. Good, Roslyn A. Stone, (unknown), (unknown), (unknown), David N. Jansen, (unknown), (unknown), (unknown), Mark A. Burlingame, (unknown), (unknown), (unknown), (unknown), Francesca Cunningham	24
6	Simple One-Pot Synthesis of Disulfide Fragments for Use in Disulfide-Exchange Screening 2011 ·ACS Combinatorial Science ·Mark A. Burlingame, (unknown), Adam R. Renslo	20
7	Turning a protein kinase on or off from a single allosteric site via disulfide trapping 2011 ·Proceedings of the National Academy of Sciences ·Jack Sadowsky, Mark A. Burlingame, Dennis W. Wolan, Christopher L. McClendon, Matthew P. Jacobson, James A. Wells	130
8	Structure−Activity Relationships of 9-Substituted-9-Dihydroerythromycin-Based Motilin Agonists: Optimizing for Potency and Safety 2009 ·Journal of Medicinal Chemistry ·Simon J. Shaw, Yue Chen, Hao Zheng, Hong Fu, Mark A. Burlingame, (unknown), Yong Li, (unknown), Christopher W. Carreras, William Crumb, Dwight J. Hardy, David C. Myles, Yaoquan Liu	10
9	Preparation of Erythromycin Analogs Having Functional Groups at C-15 2006 ·The Journal of Antibiotics ·Gary W. Ashley, Mark A. Burlingame, Ruchir P. Desai, Hong Fu, (unknown), Peter Licari, (unknown), Darren Abbanat, Karen Bush, Mark J. Macielag	19
10	A series of 23,24-dihydrodiscodermolide analogues with simplified lactone regions 2006 ·Bioorganic & Medicinal Chemistry Letters ·Simon J. Shaw, Kurt F. Sundermann, Mark A. Burlingame, Dan Zhang, (unknown), David C. Myles	8
11	Synthesis of discodermolide intermediates from engineered polyketides 2005 ·Tetrahedron Letters ·Mark A. Burlingame, (unknown), Gary W. Ashley, David C. Myles	3
12	Toward Understanding How the Lactone Moiety of Discodermolide Affects Activity 2005 ·Journal of the American Chemical Society ·Simon J. Shaw, Kurt F. Sundermann, Mark A. Burlingame, David C. Myles, B. Scott Freeze, Ming Xian, Ignacio Brouard, Amos B. Smith	48
13	Design, synthesis and cytotoxicity of 7-deoxy aryl discodermolide analogues 2004 ·Bioorganic & Medicinal Chemistry Letters ·Mark A. Burlingame, Simon J. Shaw, Kurt F. Sundermann, Dan Zhang, (unknown), (unknown), Fenghua Liu, David C. Myles, Matthew J. LaMarche, Tomoyasu Hirose, B. Scott Freeze, Amos B. Smith	20
14	Design, Synthesis, and Evaluation of Analogues of (+)-14-Normethyldiscodermolide 2004 ·Organic Letters ·Amos B. Smith, B. Scott Freeze, Matthew J. LaMarche, Tomoyasu Hirose, Ignacio Brouard, Ming Xian, Kurt F. Sundermann, Simon J. Shaw, Mark A. Burlingame, Susan Band Horwitz, David C. Myles	19
15	N-Acyl-2-benzoxazolinones in titanium-mediated aldol reactions 2004 ·Tetrahedron Letters ·Mark A. Burlingame, (unknown), Gary W. Ashley	8
16	Design, Synthesis, and Evaluation of Carbamate-Substituted Analogues of (+)-Discodermolide 2004 ·Organic Letters ·Amos B. Smith, B. Scott Freeze, Matthew J. LaMarche, Tomoyasu Hirose, Ignacio Brouard, Paul V. Rucker, Ming Xian, Kurt F. Sundermann, Simon J. Shaw, Mark A. Burlingame, Susan Band Horwitz, David C. Myles	27
17	Saccharopolyspora erythraea-catalyzed bioconversion of 6-deoxyerythronolide B analogs for production of novel erythromycins 2002 ·Journal of Biotechnology ·Christopher W. Carreras, (unknown), (unknown), (unknown), (unknown), (unknown), Timothy Leaf, John R. Carney, Mark A. Burlingame, (unknown), Gary W. Ashley, Peter Licari	26
18	Employing racemic precursors in directed biosynthesis of 6‐dEB analogs 2002 ·Journal of Chemical Technology & Biotechnology ·Timothy Leaf, Mark A. Burlingame, Ruchir P. Desai, Rika Regentin, (unknown), Gary W. Ashley, Peter Licari	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact